Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer

Breast Cancer Research

Volumn 18, Issue 1, 2016, Pages

  Hu, Zhi ^a   Mao, Jian Hua ^b   Curtis, Christina ^c   Huang, Ge ^a   Gu, Shenda ^a   Heiser, Laura ^a   Lenburg, Marc E ^d   Korkola, James E ^a   Bayani, Nora ^b   Samarajiwa, Shamith ^e   Seoane, Jose A ^c   Dane, Mark ^a   Esch, Amanda ^a   Feiler, Heidi S ^a   Wang, Nicholas J ^a   Hardwicke, Mary Ann ^f   Laquerre, Sylvie ^f   Jackson, Jeff ^f   Wood, Kenneth ^g   Weber, Barbara ^f   Spellman, Paul T ^a   Aparicio, Samuel ^h   Wooster, Richard ^f   Caldas, Carlos ⁱ   Gray, Joe W ^a   more..

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f GLAXOSMITHKLINE   (United States)

^g Cytokinetics Inc   (United States)

^h BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

ⁱ IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Breast cancer; Mitotic index; Novel therapeutics; Predictive biomarker

Indexed keywords

GSK 1070916; GSK 462364; GSK 923295; MYC PROTEIN; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; AURORA KINASE; CELL CYCLE PROTEIN; CENTROMERE PROTEIN E; NONHISTONE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST TUMOR; BUB1 GENE; BUB1B GENE; CCNA2 GENE; CCNB1 GENE; CELL GROWTH; CENPE GENE; CHEK1 GENE; CHROMOSOME 10P; CHROMOSOME 12P; CHROMOSOME 17Q; CHROMOSOME 8Q; CONTROLLED STUDY; DLGAP5 GENE; DRUG SENSITIVITY; EXO1 GENE; FOXM1 GENE; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GSTE1 GENE; HJURP GENE; HUMAN; HUMAN CELL; KIF2C GENE; MCM10 GENE; MITOSIS INDEX; MITOSIS RATE; MITOTIC NETWORK ACTIVITY INDEX; NCAPD2 GENE; NCAPG GENE; NCAPH GENE; NDC80 GENE; PLK1 GENE; PTTG1 GENE; RFC3 GENE; SMC4 GENE; SURVIVAL TIME; TTK GENE; TYMS GENE; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN GENOME; KAPLAN MEIER METHOD; METABOLISM; MITOSIS; MOLECULAR LIBRARY; PHARMACOLOGY; PROCEDURES; PROGNOSIS; RNA INTERFERENCE; TREATMENT OUTCOME; TUMOR CELL LINE;

AURORA KINASES; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMAL PROTEINS, NON-HISTONE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENOME, HUMAN; HUMANS; KAPLAN-MEIER ESTIMATE; MITOSIS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; SMALL MOLECULE LIBRARIES; TREATMENT OUTCOME;

EID: 84977126607     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-016-0728-y     Document Type: Article

References (45)

1. Gaillard H, García-Muse T, Aguilera A. Replication stress and cancer. Nat Rev Cancer. 2015;15:276-89.
2. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta. 1785;2008:50-72.
3. Curtis C. Genomic profiling of breast cancers. Curr Opin Obstet Gynecol. 2015;27(1):34-9.
4. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006;38:1043-8.
5. Medri L, Volpi A, Nanni O, Vecci AM, Mangia A, Schittulli F, et al. Prognostic relevance of mitotic activity in patients with node-negative breast cancer. Mod Pathol. 2003;15:1057-75.
6. Strebhardt K, Becker S, Matthess Y. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery. Expert Opin Drug Discov. 2015;10(1):1-8.
7. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol. 2004;5(5):429-40.
8. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature. 2001;410:215-20.
9. McInnes C, Mazumdar A, Mezena M, Meades C, Midgley C, Scaerou F, et al. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol. 2005;2:508-17.
10. Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y, et al. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene. 2004;23:5901-11.
11. Li Y, Zhang ZF, Chen J, Huang D, Ding Y, Tan MH, et al. VX580/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res. 2010;2:295-308.
12. Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, et al. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle. 2009;8:1921-9.
13. Wood KW, Chua P, Sutton D, Jackson JR, et al. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci USA. 2010;107:5839-44.
14. Pérez-Melero C. KSP inhibitors as antimitotic agents. Curr Top Med Chem. 2014;14:2286-311.
15. Quigley DA, To MD, Perez-Losada J, Pelorosso FG, Mao JH, Nagase H, et al. Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature. 2009;458:505-8.
16. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, et al. Identification of Stk5/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet. 2003;34:403-12.
17. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet. 2003;33(Suppl):238-44.
18. Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009;14:559-70.
19. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK462364A, including differential effect on apoptosis. Cancer Res. 2009;59:5959-77.
20. Wood KW, Chua P, Sutton D, Jackson JR. Centromere-associated protein E: a motor that puts the brakes on the mitotic checkpoint. Clin Cancer Res. 2008;14:7588-92.
21. Anderson K, Lai Z, McDonald OB, Stuart JD, Nartey EN, Hardwicke MA, et al. Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time. Biochem J. 2009;420:259-65.
22. Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, et al. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010;53:3973-4001.
23. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2005;10:515-27.
24. van de Wiel MA, van Wieringen WN. CGH regions: dimension reduction for array CGH data with minimal information loss. Cancer Inform. 2007;3:55-63.
25. Barbosa-Morais NL, Dunning MJ, Samarajiwa SA, Darot JF, Ritchie ME, Lynch AG, et al. A re-annotation pipeline for Illumina Bead Arrays: improving the interpretation of gene expression data. Nucleic Acids Res. 2009;38(3):e17-30.
26. Korde LA, Lusa L, McShane L, Lebowitz PF, Lukes L, Camphausen K, et al. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat. 2010;119(3):585-99.
27. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346-52.
28. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 2005;21(15):3448-9.
29. Kel AE, Gössling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, Wingender E. MATCH: a tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res. 2003;31:3576-9.
30. Krull M, Voss N, Choi C, Pistor S, Potapov A, Wingender E. TRANSPATH: an integrated database on signal transduction and a tool for array analysis. Nucleic Acids Res. 2003;31:97-100.
31. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;355(9450):571-9.
32. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005;7:R953-4.
33. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2005;55:10292-301.
34. Manders P, Bult P, Sweep CG, Tjan-Heijnen VC, Beex LV, et al. The prognostic value of the mitotic activity index in patients with primary breast cancer who were not treated with adjuvant systemic therapy. Breast Cancer Res Treat. 2003;77:77-84.
35. Russ AP, Lampel S. The druggable genome: an update. Drug Discov Today. 2005;10:1507-10.
36. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, et al. MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol. 2007;27:4513-25.
37. Hirsch CL, Coban Akdemir Z, Wang L, Jayakumaran G, Trcka D, Weiss A, et al. Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming. Genes Dev. 2015;29(8):803-16.
38. Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, et al. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014;74:520-31.
39. Liu JA, Wu MH, Yan CH, Chau BK, So H, Ng A, et al. Phosphorylation of Sox9 is required for neural crest delamination and is regulated downstream of BMP and canonical Wnt signaling. Proc Natl Acad Sci USA. 2013;110:2882-7.
40. Martini S, Bernoth K, Main H, Ortega GD, Lendahl U, Just U, et al. A critical role for Sox9 in notch-induced astrogliogenesis and stem cell maintenance. Stem Cells. 2013;31:741-51.
41. Bergamaschi A, Madak-Erdogan Z, Kim YJ, Choi YL, Lu H, Katzenellenbogen BS. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Breast Cancer Res. 2014;16:436-53.
42. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 2005;65:4059-66.
43. Starmans MH, Krishnapuram B, Steck H, Horlings H, Nuyten DS, van de Vijver MJ, et al. Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer. 2008;99:1884-90.
44. Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop J. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci. 2010;07:13836-41.
45. Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, Moss K, et al. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther. 2009;8:1808-17.